At the news
? NEUTRALIMPACT 2/10 CLUSTER filed May 4, 2026 at 16:54 ET
Three insiders at United Therapeutics sold a total of $377K in open-market sales over a 7-day window, immediately following the release of Q1 2026 earnings that showed a 2% revenue decline and a 15% drop in net income. The sales are trivial relative to the company's $24B market cap (0.0016%), and the CEO's trades are part of a routine derivative exercise-and-sell pattern. The cluster does not signal material insider concern.
- Total open-market sales: $377K across 3 insiders (CEO, EVP & General Counsel, CFO)
- Sales represent 0.0016% of UTHR's $24B market cap, immaterial
- CEO Martine Rothblatt's sales ($354K) are part of a pre-planned derivative exercise pattern (9,500 shares exercised at $0 and $146.03, then sold small lots)
- Q1 2026 earnings filed 5 days prior: revenue down 2% YoY to $781.5M, net income down 15% to $274.9M
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access